Not investment advice. Educational platform. See Disclaimer.
NASDAQ: GUTS
Fractyl Health, Inc. Common Stock
Healthcare | Biotechnology
No licensed closing price on file for GUTS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Fractyl Health, Inc. Common Stock (NASDAQ: GUTS) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 12:30 UTC.
What Fractyl Health, Inc. Common Stock does
The company is a clinical-stage metabolic therapeutics developer focused on treating obesity and type 2 diabetes through novel approaches targeting root causes rather than chronic symptom management. Its lead product candidate, Revita, uses hydrothermal ablation to remodel the duodenal lining and help patients maintain weight loss after discontinuing GLP-1 therapy, and has received FDA Breakthrough Device designation.
Summarized from Fractyl Health, Inc. Common Stock’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
2025-09-03Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersSheffield's BoardEstimatedSEC 8-K →
The company is a clinical-stage metabolic therapeutics developer focused on treating obesity and type 2 diabetes through novel approaches targeting root causes rather than chronic symptom management.
When did GUTS last file with the SEC?
Fractyl Health, Inc. Common Stock's most recent SEC filing on record is a 8-K filed 2026-10-16. All filings link to their SEC EDGAR originals above.
Where does this data come from?
SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 12:30 UTC. This page is also available as JSON at /api/data?ticker=GUTS and is emitted with FAQPage structured data for machine reading.
For you
Charts, 10-year financials, peer comparison, screening and portfolio tracking for GUTS and 5,000+ tickers.